Regulus Therapeutics Stock Price Up 9.5% Following Analyst Upgrade (RGLS)
Shares of Regulus Therapeutics (NASDAQ:RGLS) traded up 9.5% during trading on Monday after Wedbush raised their price target on the stock from $17.00 to $19.00, AnalystRatingsNetwork reports. The company traded as high as $9.47 and last traded at $9.47, with a volume of 174,373 shares changing hands. The stock had previously closed at $8.65.
A number of other firms have also recently commented on RGLS. Analysts at TheStreet upgraded shares of Regulus Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, January 20th. Analysts at Cowen and Company reiterated an “outperform” rating on shares of Regulus Therapeutics in a research note on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $15.25.
In other Regulus Therapeutics news, major shareholder Sanofi purchased 1,303,780 shares of the stock in a transaction dated Tuesday, February 4th. The stock was purchased at an average cost of $7.67 per share, for a total transaction of $9,999,992.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
The stock’s 50-day moving average is $7.89 and its 200-day moving average is $8.09. The company’s market cap is $400.2 million.
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing first-in-class drugs that target microRNAs to treat a range of diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.